Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof

Issuing agencies

Abstract

The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Korea National Institute of Health, located in Cheongju-si, Chungcheongbuk-do, South Korea to practice the invention embodied in the patent application listed in the Supplementary Information section of this notice.

Full Text

<html>
<head>
<title>Federal Register, Volume 91 Issue 195 (Friday, October 9, 2026)</title>
</head>
<body><pre>
[Federal Register Volume 91, Number 195 (Friday, October 9, 2026)]
[Notices]
[Page 64672]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2026-20705]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive License, Inter-Institutional 
Agreement-Institution Lead: Antibody Specifically Binding to Severe 
Fever With Thrombocytopenia Syndrome Virus Antigen and Use Thereof

AGENCY: National Institutes of Health, National Institute of Allergy 
and Infectious Diseases.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institute of Allergy and Infectious Diseases, an 
institute of the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of an exclusive, 
sublicensable patent license to Korea National Institute of Health, 
located in Cheongju-si, Chungcheongbuk-do, South Korea to practice the 
invention embodied in the patent application listed in the 
Supplementary Information section of this notice.

DATES: Only written comments and/or applications for a license which 
are received by the Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases on or 
before October 26, 2026 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated exclusive patent license 
should be directed to: Brian Bailey, Ph.D., Senior Technology Transfer 
and Patent Specialist, Technology Transfer and Intellectual Property 
Office, National Institute of Allergy and Infectious Diseases, 5601 
Fishers Lane, Suite 2G, MSC9804, Rockville, MD 20852-9804, phone number 
240-669-5128, or <a href="/cdn-cgi/l/email-protection#d5b7a7bcb4bbfbb7b4bcb9b0ac95bbbcbdfbb2baa3"><span class="__cf_email__" data-cfemail="4a2838232b2464282b23262f330a242322642d253c">[email&#160;protected]</span></a>.

SUPPLEMENTARY INFORMATION: The following represents the intellectual 
property to be licensed under the prospective agreement: Korean Patent 
Application No. 10-2025-0196127, filed December 11, 2025, titled ``An 
Antibody Specifically Binding to Severe Fever with Thrombocytopenia 
Syndrome Virus Antigen and Use thereof'' (NIH Tracking Number E-102-
2025-0). All rights in this invention have been assigned to Korea 
National Institute of Health and the Government of the United States of 
America.
    The prospective patent license will be for the purpose of 
consolidating the patent rights with Korea National Institute of 
Health, the co-owner of said rights, for commercial development and 
marketing. Consolidation of these co-owned rights is intended to 
expedite development of the invention, consistent with the goals of the 
Bayh-Dole Act codified as 35 U.S.C. 200-212.
    The prospective interinstitutional agreement will include an 
exclusive license for NIAID's rights in these jointly owned patent 
rights. It will be sublicensable, and any sublicenses granted by Korea 
National Institute of Health will be subject to the provisions of 37 
CFR part 404.
    The subject patent rights are related to novel antibodies and 
antigen-binding fragments that specifically bind the Severe Fever with 
Thrombocytopenia Syndrome (SFTS) virus envelope glycoprotein antigen, 
including Gn- and Gc-targeting antibodies, together with related 
pharmaceutical and diagnostic compositions for prevention, diagnosis, 
mitigation, or treatment of SFTS virus infection. The invention arose 
from a research collaboration between NIAID and Korea National 
Institute of Health.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and may be granted unless within fifteen (15) days from the date of 
this published notice, the National Institute of Allergy and Infectious 
Diseases receives written evidence and argument that establishes that 
the grant of the license would not be consistent with the requirements 
of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: October 6, 2026.
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2026-20705 Filed 10-8-26; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>